Sight Sciences, Inc.: insider trades · United States · SEC (Form 4)

About Sight Sciences, Inc.

Sight Sciences, Inc. (ticker: SGHT) is a United States-based ophthalmic medical technology company listed on the Nasdaq market in the United States. Incorporated in Delaware in 2010 and headquartered in Menlo Park, California, the company has built its identity around interventional eye-care technologies aimed at improving treatment pathways in glaucoma and dry eye disease. Its business model is that of a specialized medtech platform rather than a broad-based medical device franchise. Sight Sciences operates through two core commercial areas. The Surgical Glaucoma segment is anchored by the OMNI family of products, including OMNI and the newer OMNI Edge system, which are designed for minimally invasive glaucoma surgery (MIGS). These devices are intended to lower intraocular pressure by addressing the eye’s conventional outflow pathways. The Dry Eye segment centers on TearCare, a therapeutic heat-based system used for meibomian gland dysfunction-associated dry eye disease, along with related consumables and accessories. This gives the company two distinct but complementary growth vectors within ophthalmology. From a competitive standpoint, Sight Sciences targets clinically meaningful niches in highly regulated markets. Its positioning depends on product innovation, physician adoption, evidence generation, and reimbursement progress. In glaucoma, the company competes in the MIGS category against larger ophthalmology and medtech players; in dry eye, it faces both procedure-based and drug-based alternatives. Management has consistently emphasized clinical data, peer-reviewed publications, and health-economic support as key levers for adoption and market access. For investors, that means the company’s commercial trajectory is closely linked to how quickly physicians, payers, and hospitals adopt its procedures. Geographically, Sight Sciences remains primarily U.S.-focused, with the United States as its main commercial market and operational base. Its trademarks and product development have broader reach, but revenue generation is still concentrated domestically. The company does not intend to pay cash dividends and instead reinvests available capital into product development, commercialization, and reimbursement initiatives. Recent developments have centered on the rollout of OMNI Edge, ongoing efforts to build commercial momentum in MIGS, and the push to establish more favorable reimbursement for TearCare. In 2025, management highlighted these priorities in quarterly updates, and the company’s 2026 full-year results showed a modest recovery in quarterly revenue late in the year alongside lower adjusted operating expenses. For international equity investors, SGHT is best viewed as a Nasdaq-listed U.S. ophthalmic medtech story with meaningful upside potential, but also with sensitivity to reimbursement policy, procedural adoption rates, and execution risk.